Madhu Ramaswamy, PhD

ASTRAZENECA
Gaithersburg, MD, United States

To be Added

Disclosure information not submitted.

Presentation(s):

• 0975: Modulation of T, B, and Innate Cell-Associated Pharmacodynamic Biomarkers in a Phase 3 Trial of Anifrolumab in Moderate to Severe SLE

  Sunday, November 13, 2022
  9:00 AM – 10:30 AM Eastern Time